Tvardi Therapeutics, Inc. (TVRD) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+179.3%

$2.25

vs $0.81 price

Levered DCF

$2.64

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-13.58

Distress zone

Rating

B-

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	-1.75×	-0.11×	-2.65×	-2.23×	-0.08×	0.77×
P/B	1.52×	-1.62×	-0.74×	-1.02×	0.03×	0.03×
P/S	0×	1.04×	2.19×	1.09×	0.3×	0.05×
EV / EBITDA	-0.63×	-0.22×	-0.2×	-0.31×	0.03×	-2.28×
Gross margin	0.0%	88.6%	69.3%	82.1%	93.3%	0.0%
Operating margin	0.0%	-781.6%	-579.4%	-209.1%	-386.8%	4.0%
Net margin	0.0%	-993.0%	-565.2%	-204.2%	-384.1%	6.2%
Current ratio	2.86×	11.03×	7.97×	10.31×	9.84×	10.55×
Debt / equity	0.01×	-9.68×	-0.01×	-0.05×	0.02×	0.02×
Interest coverage	0×	-6.58×	0×	-29,178.33×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	-87.0%	1542.9%	191.0%	189.7%	-38.9%	3.4%
Return on invested capital	-126.5%	-139.2%	-510.2%	-204.4%	-38.5%	2.1%
Return on assets	-56.8%	-161.7%	-438.9%	-189.5%	-35.8%	3.1%
Free cash flow yield	-73.7%	-831.4%	-206.0%	-39.1%	-871.0%	-90.4%
Earnings yield	-57.1%	-950.9%	-258.5%	-186.5%	-1281.1%	130.3%
Enterprise value	$11.4M	$14M	$23.3M	$26.7M	-$2.9M	-$20M
Net debt / EBITDA	1.13×	-0.1×	0.19×	0.22×	0.11×	-3.02×
Cash conversion cycle (days)	-12,368	-10	-21	-78	-696	6